Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2016-09-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/4/1/53.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861418933354496 |
|---|---|
| author | Ann W. Silk Howard L. Kaufman Hasan Rehman Michael P. Kane |
| author_facet | Ann W. Silk Howard L. Kaufman Hasan Rehman Michael P. Kane |
| author_sort | Ann W. Silk |
| collection | DOAJ |
| description | With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow, and so far has been largely limited to specialized cancer centers. Limiting factors include the intratumoral route of administration, which is unfamiliar to medical oncologists, biosafety concerns related to the use of a live virus in the clinic, and the explosion of other therapeutic strategies now available for the treatment of advanced melanoma. Herein, we review the development of T-VEC, and suggest how it fits into the in the current clinical treatment paradigm, and provide pearls for drug preparation, administration, and monitoring of response to therapy. |
| format | Article |
| id | doaj-art-946fee4db18744039fafcaa03bfdddcd |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2016-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-946fee4db18744039fafcaa03bfdddcd2025-02-09T14:05:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262016-09-014110.1186/s40425-016-0158-5Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyAnn W. Silk0Howard L. Kaufman1Hasan Rehman2Michael P. Kane3Aff1 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street, Room 2508B 08901 New Brunswick NJ USAAff1 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street, Room 2508B 08901 New Brunswick NJ USAAff1 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street, Room 2508B 08901 New Brunswick NJ USAAff1 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street, Room 2508B 08901 New Brunswick NJ USAWith the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow, and so far has been largely limited to specialized cancer centers. Limiting factors include the intratumoral route of administration, which is unfamiliar to medical oncologists, biosafety concerns related to the use of a live virus in the clinic, and the explosion of other therapeutic strategies now available for the treatment of advanced melanoma. Herein, we review the development of T-VEC, and suggest how it fits into the in the current clinical treatment paradigm, and provide pearls for drug preparation, administration, and monitoring of response to therapy.https://jitc.bmj.com/content/4/1/53.full |
| spellingShingle | Ann W. Silk Howard L. Kaufman Hasan Rehman Michael P. Kane Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy Journal for ImmunoTherapy of Cancer |
| title | Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy |
| title_full | Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy |
| title_fullStr | Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy |
| title_full_unstemmed | Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy |
| title_short | Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy |
| title_sort | into the clinic talimogene laherparepvec t vec a first in class intratumoral oncolytic viral therapy |
| url | https://jitc.bmj.com/content/4/1/53.full |
| work_keys_str_mv | AT annwsilk intotheclinictalimogenelaherparepvectvecafirstinclassintratumoraloncolyticviraltherapy AT howardlkaufman intotheclinictalimogenelaherparepvectvecafirstinclassintratumoraloncolyticviraltherapy AT hasanrehman intotheclinictalimogenelaherparepvectvecafirstinclassintratumoraloncolyticviraltherapy AT michaelpkane intotheclinictalimogenelaherparepvectvecafirstinclassintratumoraloncolyticviraltherapy |